LA CREIS RENEE KIDD

Summary

Affiliation: University of Louisville
Country: USA

Publications

  1. ncbi Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, University of Louisville Clinical Translational Research Building, 505 South Hancock Street Room 306, Louisville, KY, 40202, USA
    Hered Cancer Clin Pract 10:16. 2012
  2. ncbi Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer
    Nicole A Lavender
    Department of Pharmacology and Toxicology, School of Medicine, University of Louisville UofL, Louisville, KY, USA
    BMC Med Genomics 5:11. 2012
  3. ncbi 8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study
    Marnita L Benford
    Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
    BMC Cancer 10:334. 2010
  4. ncbi Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA
    Cancer Causes Control 21:1545-57. 2010
  5. ncbi Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center, 505 S Hancock St, Louisville, KY 40292, USA
    Biochem Genet 49:73-82. 2011

Research Grants

  1. A Pharmacogenetic approach to prostate cancer susceptibility
    LA CREIS KIDD; Fiscal Year: 2007

Collaborators

Detail Information

Publications5

  1. ncbi Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, University of Louisville Clinical Translational Research Building, 505 South Hancock Street Room 306, Louisville, KY, 40202, USA
    Hered Cancer Clin Pract 10:16. 2012
    ..abstract:..
  2. ncbi Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer
    Nicole A Lavender
    Department of Pharmacology and Toxicology, School of Medicine, University of Louisville UofL, Louisville, KY, USA
    BMC Med Genomics 5:11. 2012
    ..This statistical conundrum stems from the prohibitive amount of data needed to account for multiple hypothesis testing...
  3. ncbi 8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study
    Marnita L Benford
    Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, USA
    BMC Cancer 10:334. 2010
    ..Human chromosome 8q24 has been implicated in prostate tumorigenesis...
  4. ncbi Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA
    Cancer Causes Control 21:1545-57. 2010
    ..Consequently, we evaluated the influence of 14 sequence variants detected in IL-10, TGF-β1, VEGF, and their associated receptors as effective predictors of BrCA clinical outcomes...
  5. ncbi Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland
    LaCreis R Kidd
    Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center, 505 S Hancock St, Louisville, KY 40292, USA
    Biochem Genet 49:73-82. 2011
    ..28; 95% CI, 0.66-2.47), aggressive disease (OR = 0.58; 95% CI, 0.13-2.67), or advanced disease (OR = 1.19; 95% CI, 0.49-2.91)...

Research Grants2

  1. A Pharmacogenetic approach to prostate cancer susceptibility
    LA CREIS KIDD; Fiscal Year: 2007
    ....